Ethosuximide (Epilepsy)

Neural Tube Defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6495
R17805		 Bànhidy (Ethosuximide), 2011 Neural tube defects throughout pregnancy case control unexposed, sick Adjustment: No Matched 19.00 [0.15;2409.97] C 0/   1/11 1 0
ref
S6065
R15774		 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 Neural tube defect 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 18.71 [0.72;484.16] C 0/12   1/647 1 12
ref
Total 2 studies 18.80 [1.26;279.89] 2 12
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Ethosuximide), 2011Bànhidy, 2011 1 19.00[0.15; 2409.97]1-31%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 18.71[0.72; 484.16]11269%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 18.80[1.26; 279.89]2120.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide; 2: Ethosuximide) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 18.71[0.72; 484.16]112 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 case control studiescase control studies 19.00[0.15; 2409.97]1- -NABànhidy (Ethosuximide), 2011 1 Type of controls unexposed, sickunexposed, sick 19.00[0.15; 2409.97]1- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sickexposed to other treatment, sick 18.71[0.72; 484.16]112 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 18.80[1.26; 279.89]2120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 2 MatchedMatched 19.00[0.15; 2409.97]1- -NABànhidy (Ethosuximide), 2011 1 All studiesAll studies 18.80[1.26; 279.89]2120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale19.00[0.15; 2409.97]1- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale18.71[0.72; 484.16]112 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0